Life Sciences

Taro plant doesn't meet GMP requirements, FDA says

Pharma Compliance Alert, February 18, 2009

FDA inspectors found significant deviations from current Good Manufacturing Practices (cGMP) at Taro Pharmaceuticals’ Brampton, Ontario, manufacturing facility, according to an FDA warning letter.

The agency considers the products misbranded because they were not manufactured, processed, packed, and held in compliance with cGMPs. While Taro implemented some corrective actions, the FDA said the company failed to adequately address multiple serious deficiencies.

Most Popular